1 completed, 1 recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Relatlimab + Nivolumab: new trials by email Literature Review of Relatlimab + Nivolumab trials Research Report on Relatlimab + Nivolumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma Fianlimab + Cemiplimab, Relatlimab + Nivolumab - Locally Advanced Melanoma | Recruiting | John Kirkwood | 20 | 2025-11-19 | 2025-11-26 | |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Relatlimab + Nivolumab, Nivolumab, Paclitaxel - Gastric Cancer, Cancer of the Stomach | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2019-10-31 | 2020-05-19 | |
| Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting Relatlimab, Nivolumab, Relatlimab + Nivolumab - Melanoma | Phase 2 | Completed | John Kirkwood | 43 | 2019-03-29 | 2026-08-31 |
Melanoma (1) · Stomach Neoplasms (1)
John Kirkwood (2) · Bristol-Myers Squibb (1)
United States (3) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Germany (1) · Italy (1) · Mexico (1) · Portugal (1) · Puerto Rico (1) · Romania (1) · Spain (1)
John Kirkwood, MD (1) · John M Kirkwood, MD (1)
2018 (1)